Aviptadil: complete guide

Aviptadil is synthetic vasoactive intestinal peptide (VIP), tested as Zyesami for COVID-19. This guide covers its structure, mechanism, trials, side effects and status.

Complete guide5 min read

Key takeaway

Aviptadil has a molecular weight of 3,326.8 g/mol. FDA declined emergency use authorization for it in November 2021 and again in July 2022, its developer reported. In the 471-patient TESICO trial, day-90 deaths were 38% with aviptadil and 36% with placebo.

At a glance

Article typeComplete guide
Regulatory statusNot FDA-approved“Aviptadil is not approved by the FDA for any use.” (this article)
ClassImmune & inflammation
Body systemsImmune system
Studies cited2 in this article · 2 across 1 article on Aviptadil
Related productsBPC-157, TB-500 and thymic peptides

Aviptadil is a synthetic copy of vasoactive intestinal peptide (VIP), a 28-amino-acid neuropeptide the human body makes. It was tested as a COVID-19 treatment under the name Zyesami. This guide covers its structure, mechanism, trials, reported side effects and regulatory history. Sources were checked on November 17, 2026.

Quick answer: Aviptadil is synthetic human VIP. It acts on the VPAC1 and VPAC2 receptors, which relax smooth muscle and modulate immune activity. Large COVID-19 trials did not show a significant benefit on their primary outcomes. It is not FDA-approved. In the UK, a combination with phentolamine called Invicorp is used for erectile dysfunction.

Vitrapep does not sell aviptadil; this page is a reference summary of published research and regulatory information.

What is aviptadil?

Aviptadil is the drug name for synthetic VIP. A 2022 trial report calls it “aviptadil (synthetic VIP)” in its title (Youssef et al., 2022). In people, VIP is cut from a larger precursor protein. UniProt lists the mature VIP as 28 amino acids, with an amidated asparagine at its end (UniProt P01282).

Because it is a single chain of 28 amino acids, VIP is a classic peptide hormone. Our guide to peptide hormones covers the wider group. The NCBI gene record places VIP in the glucagon family, along with secretin and glucagon (NCBI Gene, VIP).

PubChem lists aviptadil with the formula C147H237N43O43S and a molecular weight of 3,326.8 g/mol (PubChem CID 16132300). Other names include Zyesami and the research code RLF-100.

Table 1

Aviptadil: key facts

Fact Detail
Structure type Linear peptide, 28 amino acids, C-terminal amide (synthetic human VIP)
Class VIP receptor (VPAC1 and VPAC2) agonist; glucagon peptide family
Molecular formula C147H237N43O43S
Molecular weight 3,326.8 g/mol
Development stage Phase 2/3 and Phase 3 COVID-19 trials completed (2021 to 2022); FDA declined emergency use authorization (2021, 2022)
Sponsor or developer NeuroRx and Relief Therapeutics (2020); NRx Pharmaceuticals (EUA requests); registry sponsor now APR Applied Pharma Research
Approved outside the US United Kingdom: Invicorp (with phentolamine) for erectile dysfunction; accepted for restricted NHS Scotland use in 2017

How does aviptadil work?

Aviptadil works the way natural VIP does. UniProt states that VIP acts on two class B1 G protein-coupled receptors, VPAC1 and VPAC2 (UniProt P01282). The NCBI gene summaries say these receptors activate adenylate cyclase through a G protein.

According to the same records, VIP relaxes smooth muscle in the airways, stomach and gallbladder. It widens blood vessels and lowers blood pressure. In lung and gut lining, its receptors help control secretion and the movement of fluid and ions. UniProt adds roles in neuroprotection and immune modulation. These are descriptions of the natural peptide’s biology, not proof of a treatment effect.

What is aviptadil being studied for?

Aviptadil is not approved by the FDA for any use. ClinicalTrials.gov lists nine studies that name it. All involve COVID-19, mostly with respiratory failure or lung injury. Key entries are below.

  • critical COVID-19 with respiratory failure, Phase 2/3, 196 randomized (NCT04311697, completed 2021);
  • severely ill inpatients with COVID-19, ACTIV-3b/TESICO, Phase 3, run by NIAID (NCT04843761, completed 2022);
  • COVID-19 patients at high risk for ARDS, Phase 2 (NCT04536350, terminated 2023); and
  • an aviptadil arm in the I-SPY COVID platform trial, now listed as closed (NCT04488081).

No aviptadil study is recruiting. In 2020, NeuroRx and Relief Therapeutics announced that FDA granted an expanded access protocol for COVID-19 respiratory failure. The release headline said development was under Fast Track designation (NeuroRx and Relief, 2020).

What did the key trials show?

COVID-AIV (NCT04311697). This human trial randomized 196 patients with critical COVID-19 respiratory failure, 2:1 to aviptadil or placebo. The primary endpoint was being “alive and free from respiratory failure at day 60.” It was not statistically significant (odds ratio 1.6; 95% CI 0.86 to 3.11). The authors reported better 60-day survival as a secondary finding (odds ratio 2.0; p = 0.035) (Youssef et al., 2022).

TESICO (NCT04843761). This NIH-sponsored, placebo-controlled human trial randomized 471 hospitalized adults with COVID-19 hypoxaemic respiratory failure. The primary outcome was a six-level recovery scale at day 90. The odds ratio was 1.11 (95% CI 0.80 to 1.55; p = 0.54). Day-90 mortality was 38% with aviptadil and 36% with placebo. The authors concluded that aviptadil “did not significantly improve clinical outcomes up to day 90” (Brown et al., 2023).

What side effects have studies reported?

The COVID-AIV results posted on ClinicalTrials.gov list 131 aviptadil and 65 placebo patients. Diarrhea was the clearest difference: 43 on aviptadil versus 1 on placebo. Low blood pressure affected 34 versus 14. Flushing affected 13 versus 2, and atrial fibrillation 15 versus 3. Serious adverse events occurred in 58 aviptadil and 32 placebo patients. Deaths were 46 and 30.

In TESICO, a combined safety outcome through day 5 included death, serious adverse events, organ failure, serious infection and grade 3 or 4 events. It occurred in 63% of aviptadil patients and 56% of placebo patients (odds ratio 1.40; p = 0.10). These patients were critically ill, so many events reflect COVID-19 itself.

What is aviptadil’s regulatory status, and how is it used in research?

On November 4, 2021, NRx Pharmaceuticals reported that FDA declined to issue an emergency use authorization for Zyesami. FDA cited “insufficient data regarding the known and potential benefits of the medicine” and its risks (NRx, 2021). On July 1, 2022, NRx reported a second decline, for a subgroup who also received remdesivir (NRx, 2022).

FDA keeps a list of bulk substances nominated for 503A compounding. Its May 14, 2026 update places “Vasoactive Intestinal Peptide” in Category 1, “Bulk Drug Substances Under Evaluation” (FDA, 2026). That is not an approval. Our page on 503A and 503B compounding explains the categories.

Outside the US, the Scottish Medicines Consortium accepted aviptadil with phentolamine (Invicorp) for restricted NHS use in December 2017. The indication is erectile dysfunction in adult men (SMC, 2017).

Frequently asked questions about aviptadil

Is aviptadil the same as VIP?

Yes. Aviptadil is the drug name for synthetic vasoactive intestinal peptide, a 28-amino-acid peptide.

Is aviptadil FDA-approved?

No. FDA declined emergency use authorization twice, and no marketing approval exists in the US.

Did aviptadil work for COVID-19?

Neither large randomized trial met its primary outcome. TESICO found no significant difference from placebo at day 90.

What is Zyesami?

Zyesami is the brand name NRx Pharmaceuticals used for aviptadil in its COVID-19 program.

What is the compounding status of VIP?

FDA lists VIP in 503A Category 1, meaning the substance is still under evaluation for the compounding bulks list.

What to know now

  • Structure: synthetic human VIP; 28 amino acids; 3,326.8 g/mol.
  • Mechanism: activates VPAC1 and VPAC2 receptors; relaxes smooth muscle and widens blood vessels.
  • Evidence: COVID-AIV and TESICO did not meet their primary outcomes.
  • Safety: more diarrhea, low blood pressure and flushing than placebo in COVID-AIV.
  • Status: not FDA-approved; EUA declined in 2021 and 2022; VIP in 503A Category 1.

What we’re watching

FDA updates to the 503A Category 1 list that includes vasoactive intestinal peptide. Any new aviptadil trial registered on ClinicalTrials.gov. Related guides: nangibotide and secretin.

More for immune system

All 24 compounds for immune system

Sources: National Center for Biotechnology Information 2026, PubChem compound summary for CID 16132300, aviptadil; UniProt Consortium 2026, UniProtKB P01282: VIP peptides (Homo sapiens); National Center for Biotechnology Information 2026, Gene ID 7432, VIP vasoactive intestinal peptide (Homo sapiens); Youssef 2022, Critical Care Medicine, 50; APR Applied Pharma Research s.a 2020, Intravenous aviptadil for critical COVID-19 with respiratory failure; Brown 2023, The Lancet Respiratory Medicine, 11; National Institute of Allergy and Infectious Diseases 2021, ACTIV-3b: Therapeutics for severely ill inpatients with COVID-19; Leuppi 2021, Inhaled aviptadil for the treatment of COVID-19 in patients at high risk for ARDS; QuantumLeap Healthcare Collaborative 2020, I-SPY COVID-19 trial: An adaptive platform trial for critically ill patients; NeuroRx 2020; NRx Pharmaceuticals 2021; NRx Pharmaceuticals 2022; U.S. Food and Drug Administration 2026; Scottish Medicines Consortium 2017, Aviptadil/phentolamine mesilate (Invicorp). All 14 citations

Back to the research library

References

  1. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 16132300, aviptadil. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/16132300
  2. UniProt Consortium. (2026). UniProtKB P01282: VIP peptides (Homo sapiens). Retrieved November 17, 2026, from https://www.uniprot.org/uniprotkb/P01282/entry
  3. National Center for Biotechnology Information. (2026). Gene ID 7432, VIP vasoactive intestinal peptide (Homo sapiens). Retrieved November 17, 2026, from https://www.ncbi.nlm.nih.gov/gene/7432
  4. Youssef, J. G., et al. (2022). Results of a 60-day randomized controlled trial of intravenous aviptadil (synthetic VIP) in critical COVID-19 respiratory failure. Critical Care Medicine, 50(11), 1545-1554. https://doi.org/10.1097/CCM.0000000000005660
  5. APR Applied Pharma Research s.a. (2020). Intravenous aviptadil for critical COVID-19 with respiratory failure (ClinicalTrials.gov ID NCT04311697). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT04311697
  6. Brown, S. M., et al. (2023). Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): A randomised, placebo-controlled trial. The Lancet Respiratory Medicine, 11(9), 791-803. https://doi.org/10.1016/S2213-2600(23)00147-9
  7. National Institute of Allergy and Infectious Diseases. (2021). ACTIV-3b: Therapeutics for severely ill inpatients with COVID-19 (ClinicalTrials.gov ID NCT04843761). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT04843761
  8. Leuppi, J. (2021). Inhaled aviptadil for the treatment of COVID-19 in patients at high risk for ARDS (ClinicalTrials.gov ID NCT04536350). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT04536350
  9. QuantumLeap Healthcare Collaborative. (2020). I-SPY COVID-19 trial: An adaptive platform trial for critically ill patients (ClinicalTrials.gov ID NCT04488081). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT04488081
  10. NeuroRx, Inc., & Relief Therapeutics Holding AG. (2020, July 29). FDA grants expanded access protocol to RLF-100 (aviptadil) for respiratory failure in COVID-19, currently in development by NeuroRx and Relief Therapeutics under Fast Track designation [Press release]. https://prnewswire.com/news-releases/fda-grants-expanded-access-protocol-to-rlf-100-aviptadil-for-respiratory-failure-in-covid-19-currently-in-development-by-neurorx-and-relief-therapeutics-under-fast-track-designation-301101816.html
  11. NRx Pharmaceuticals. (2021, November 4). US Food and Drug Administration declines emergency use authorization for ZYESAMI (aviptadil) for patients with critical COVID-19 with respiratory failure [Press release]. https://www.nrxpharma.com/us-food-and-drug-administration-declines-emergency-use-authorization-for-zyesami-aviptadil-for-patients-with-critical-covid-19-with-respiratory-failure-2/
  12. NRx Pharmaceuticals. (2022, July 1). FDA declines emergency use authorization for ZYESAMI (aviptadil) for subgroup of patients with critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir [Press release]. https://www.nrxpharma.com/fda-declines-emergency-use-authorization-for-zyesami-aviptadil-for-subgroup-of-patients-with-critical-covid-19-at-immediate-risk-of-death-from-respiratory-failure-despite-treatment-with-approv/
  13. U.S. Food and Drug Administration. (2026, May 14). Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. Retrieved November 17, 2026, from https://www.fda.gov/media/94155/download
  14. Scottish Medicines Consortium. (2017, December 11). Aviptadil/phentolamine mesilate (Invicorp). Retrieved November 17, 2026, from https://scottishmedicines.org.uk/medicines-advice/aviptadilphentolamine-mesilate-invicorp-fullsubmission-128417/